RxDoctor Payments Data

Diane Krieger, MD

Endocrinology, Diabetes & Metabolism · South Miami, FLNPI 1790757037

Payments from drug & device makers

$2,786in general payments, 2019–2025

Across 100 payments — averaging $27.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$622
  • Tandem Diabetes Care, Inc.$600
  • Insulet Corporation$593
  • Amgen$223
  • Aytu Biopharma, Inc.$186
  • Medtronic$172
  • plus $390 from 12 others

What the payments were for

  • Speaking & faculty fees$60022%
  • Food & beverage$2,17478%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,786 in reported general payments places this provider in the 40th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$475,962
Medicare patients
1,102
Services billed
8,574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TymlosAbaloparatide64$194,283
OzempicSemaglutide123$178,393
MounjaroTirzepatide107$139,409
Evenity (2 Syringes)Romosozumab-Aqqg30$126,031
SynthroidLevothyroxine Sodium381$40,040
TrulicityDulaglutide19$39,618
FarxigaDapagliflozin Propanediol37$39,301
JardianceEmpagliflozin28$35,953
ProliaDenosumab21$35,600
Tresiba Flextouch U-100Insulin Degludec18$20,414
TradjentaLinagliptin11$13,297
Humalog Kwikpen U-100Insulin Lispro23$10,397
JanuviaSitagliptin Phosphate14$9,051
Levothyroxine Sodium637$6,996
Zoledronic AcidZoledronic Acid/Mannitol-Water45$5,879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$40$178,393123 claims
AmgenEvenity (2 Syringes), Prolia$223$161,63151 claims
AbbVieSynthroid$41$40,040381 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in South Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →